REPLIGEN CORP (RGEN)

US7599161095 - Common Stock

196.52  +3.12 (+1.61%)

After market: 196.52 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to RGEN. RGEN was compared to 61 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.



5

1. Profitability

1.1 Basic Checks

RGEN had positive earnings in the past year.
RGEN had a positive operating cash flow in the past year.
Each year in the past 5 years RGEN has been profitable.
Of the past 5 years RGEN 4 years had a positive operating cash flow.

1.2 Ratios

With a decent Return On Assets value of 4.61%, RGEN is doing good in the industry, outperforming 77.05% of the companies in the same industry.
Looking at the Return On Equity, with a value of 5.82%, RGEN is in the better half of the industry, outperforming 77.05% of the companies in the same industry.
With a decent Return On Invested Capital value of 1.95%, RGEN is doing good in the industry, outperforming 67.21% of the companies in the same industry.
Industry RankSector Rank
ROA 4.61%
ROE 5.82%
ROIC 1.95%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin of RGEN (17.29%) is better than 86.89% of its industry peers.
RGEN's Profit Margin has declined in the last couple of years.
RGEN has a Operating Margin of 8.34%. This is in the better half of the industry: RGEN outperforms 65.57% of its industry peers.
RGEN's Operating Margin has declined in the last couple of years.
RGEN's Gross Margin of 46.78% is in line compared to the rest of the industry. RGEN outperforms 52.46% of its industry peers.
RGEN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.34%
PM (TTM) 17.29%
GM 46.78%
OM growth 3Y-24.87%
OM growth 5Y-10.52%
PM growth 3Y-26.44%
PM growth 5Y-5.32%
GM growth 3Y-7.98%
GM growth 5Y-4.25%

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
There is no outstanding debt for RGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 13.22 indicates that RGEN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 13.22, RGEN belongs to the best of the industry, outperforming 95.08% of the companies in the same industry.
RGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 2.93
Altman-Z 13.22
ROIC/WACC0.17
WACC11.75%

2.3 Liquidity

A Current Ratio of 2.69 indicates that RGEN has no problem at all paying its short term obligations.
RGEN has a Current ratio of 2.69. This is comparable to the rest of the industry: RGEN outperforms 49.18% of its industry peers.
RGEN has a Quick Ratio of 2.11. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a Quick ratio of 2.11. This is comparable to the rest of the industry: RGEN outperforms 49.18% of its industry peers.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.11

6

3. Growth

3.1 Past

RGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.00%.
The Earnings Per Share has been growing by 18.51% on average over the past years. This is quite good.
RGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.39%.
RGEN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.91% yearly.
EPS 1Y (TTM)-39%
EPS 3Y1.39%
EPS 5Y18.51%
EPS growth Q2Q-70.13%
Revenue 1Y (TTM)-16.39%
Revenue growth 3Y20.37%
Revenue growth 5Y26.91%
Revenue growth Q2Q-29.65%

3.2 Future

The Earnings Per Share is expected to grow by 24.02% on average over the next years. This is a very strong growth
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 13.66% on average per year.
EPS Next Y4.51%
EPS Next 2Y24.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.7%
Revenue Next 2Y11.08%
Revenue Next 3Y13.66%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

3

4. Valuation

4.1 Price/Earnings Ratio

RGEN is valuated quite expensively with a Price/Earnings ratio of 94.48.
Based on the Price/Earnings ratio, RGEN is valued a bit cheaper than 63.93% of the companies in the same industry.
RGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.35.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 108.69.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN indicates a somewhat cheap valuation: RGEN is cheaper than 60.66% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.63. RGEN is valued rather expensively when compared to this.
Industry RankSector Rank
PE 94.48
Fwd PE 108.69

4.2 Price Multiples

RGEN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. RGEN is cheaper than 60.66% of the companies in the same industry.
62.30% of the companies in the same industry are more expensive than RGEN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 112.42
EV/EBITDA 86.24

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 24.02% in the coming years.
PEG (NY)20.93
PEG (5Y)5.1
EPS Next 2Y24.02%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for RGEN!.
Industry RankSector Rank
Dividend Yield N/A

REPLIGEN CORP

NASDAQ:RGEN (2/23/2024, 7:08:58 PM)

After market: 196.52 0 (0%)

196.52

+3.12 (+1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.97B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 94.48
Fwd PE 108.69
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)20.93
PEG (5Y)5.1
Profitability
Industry RankSector Rank
ROA 4.61%
ROE 5.82%
ROCE
ROIC
ROICexc
ROICexgc
OM 8.34%
PM (TTM) 17.29%
GM 46.78%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.69
Quick Ratio 2.11
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-39%
EPS 3Y1.39%
EPS 5Y
EPS growth Q2Q
EPS Next Y4.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-16.39%
Revenue growth 3Y20.37%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y